2024
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatientsCorrection: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.Peer-Reviewed Original Research
2015
Hyperthermic intraperitoneal chemotherapy for treatment of ovarian and primary peritoneal cancer: Single institutional experience
Andikyan V, Tabrizian P, Farag S, Fields J, Kolev V, Rahaman J, Fishman D, Sarpel U, Zakashansky K, Labow D. Hyperthermic intraperitoneal chemotherapy for treatment of ovarian and primary peritoneal cancer: Single institutional experience. Gynecologic Oncology 2015, 137: 173-174. DOI: 10.1016/j.ygyno.2015.01.434.Peer-Reviewed Original ResearchRole of laparoscopy in determining optimal cytoreduction in patients with ovarian, fallopian tube and primary peritoneal cancer
Andikyan V, Kim A, Sierra T, Gretz H, Zakashansky K, Segna R, Beddoe A, Dottino P, Mandeli J, Chuang L. Role of laparoscopy in determining optimal cytoreduction in patients with ovarian, fallopian tube and primary peritoneal cancer. Gynecologic Oncology 2015, 137: 103. DOI: 10.1016/j.ygyno.2015.01.255.Peer-Reviewed Original Research